Unveiling the intricacies of COVID-19: Autoimmunity, multi-organ manifestations and the role of autoantibodies
- PMID: 39007954
- DOI: 10.1111/sji.13344
Unveiling the intricacies of COVID-19: Autoimmunity, multi-organ manifestations and the role of autoantibodies
Abstract
COVID-19 is a severe infectious disease caused by a SARS-CoV-2 infection. It has caused a global pandemic and can lead to acute respiratory distress syndrome (ARDS). Beyond the respiratory system, the disease manifests in multiple organs, producing a spectrum of clinical symptoms. A pivotal factor in the disease's progression is autoimmunity, which intensifies its severity and contributes to multi-organ injuries. The intricate interaction between the virus' spike protein and human proteins may engender the generation of autoreactive antibodies through molecular mimicry. This can further convolute the immune response, with the potential to escalate into overt autoimmunity. There is also emerging evidence to suggest that COVID-19 vaccinations might elicit analogous autoimmune responses. Advanced technologies have pinpointed self-reactive antibodies that target diverse organs or immune-modulatory proteins. The interplay between autoantibody levels and multi-organ manifestations underscores the importance of regular monitoring of serum antibodies and proinflammatory markers. A combination of immunosuppressive treatments and antiviral therapy is crucial for managing COVID-19-associated autoimmune diseases. The review will focus on the generation of autoantibodies in the context of COVID-19 and their impact on organ health.
Keywords: COVID‐19; SARS‐CoV‐2; autoantibodies; autoimmunity; immunosuppressive therapy; vaccine.
© 2023 The Scandinavian Foundation for Immunology.
Similar articles
-
Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases.Front Immunol. 2021 Jan 19;11:617089. doi: 10.3389/fimmu.2020.617089. eCollection 2020. Front Immunol. 2021. PMID: 33584709 Free PMC article.
-
Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement.Mol Immunol. 2021 Sep;137:105-113. doi: 10.1016/j.molimm.2021.06.021. Epub 2021 Jun 30. Mol Immunol. 2021. PMID: 34242919 Free PMC article.
-
SARS-CoV-2 infection as a trigger of autoimmune response.Clin Transl Sci. 2021 May;14(3):898-907. doi: 10.1111/cts.12953. Epub 2021 Jan 21. Clin Transl Sci. 2021. PMID: 33306235 Free PMC article.
-
Molecular/antigenic mimicry and immunological cross-reactivity explains SARS-CoV-2-induced autoimmunity.Autoimmun Rev. 2025 Jun 24;24(7):103811. doi: 10.1016/j.autrev.2025.103811. Epub 2025 Apr 8. Autoimmun Rev. 2025. PMID: 40209971 Review.
-
Autoimmune complications of COVID-19.J Med Virol. 2022 Jan;94(1):54-62. doi: 10.1002/jmv.27292. Epub 2021 Aug 31. J Med Virol. 2022. PMID: 34427929 Free PMC article. Review.
Cited by
-
VEGF-A in COVID-19: a systematic review and meta-analytical approach to its prognostic value.Clin Exp Med. 2025 Mar 12;25(1):81. doi: 10.1007/s10238-025-01583-5. Clin Exp Med. 2025. PMID: 40075026 Free PMC article.
-
[COVID-19 vaccines efficacy and infection features in patients with systemic sclerosis: A single-center cohort study].Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Dec 18;56(6):1041-1046. doi: 10.19723/j.issn.1671-167X.2024.06.015. Beijing Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 39690767 Free PMC article. Chinese.
-
Proteomic Profiling of Human Peripheral Blood Cell Targets of IgG Induced by SARS-CoV-2: Insights into Vaccine Safety.Vaccines (Basel). 2025 Jun 27;13(7):694. doi: 10.3390/vaccines13070694. Vaccines (Basel). 2025. PMID: 40733671 Free PMC article.
-
Immunomodulatory Mechanisms Underlying Neurological Manifestations in Long COVID: Implications for Immune-Mediated Neurodegeneration.Int J Mol Sci. 2025 Jun 27;26(13):6214. doi: 10.3390/ijms26136214. Int J Mol Sci. 2025. PMID: 40649991 Free PMC article. Review.
References
REFERENCES
-
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
-
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507‐513.
-
- Pelosi P, Tonelli R, Torregiani C, et al. Different methods to improve the monitoring of noninvasive respiratory support of patients with severe pneumonia/ARDS due to COVID‐19: an update. J Clin Med. 2022;11(6):1704.
-
- Salton F, Confalonieri P, Campisciano G, et al. Cytokine profiles as potential prognostic and therapeutic markers in SARS‐CoV‐2‐induced ARDS. J Clin Med. 2022;11(11):2951.
-
- Haarhaus M, Duhanes M, Leševic N, et al. Improved immunologic response to COVID‐19 vaccine with prolonged dosing interval in haemodialysis patients. Scand J Immunol. 2022;95(5):e13152.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous